Comparative Pharmacology
Head-to-head clinical analysis: KEVZARA versus LEQEMBI IQLIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEVZARA versus LEQEMBI IQLIK.
KEVZARA vs LEQEMBI IQLIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
200 mg subcutaneously once weekly.
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
None Documented
None Documented
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route.
Category C
Category C
Monoclonal Antibody, IL-6 Receptor Antagonist
Monoclonal Antibody